| answer text |
<p>Generally antibiotic use is determined locally and is driven by microbiology departments
and by local antibiotic resistance patterns. There are two specific areas of specialised
commissioning where provisions for antibiotics are relevant. A national policy for
cystic fibrosis is already available (<a href="http://www.england.nhs.uk/wp-content/uploads/2013/04/a01-ps-a.pdf"
target="_blank">http://www.england.nhs.uk/wp-content/uploads/2013/04/a01-ps-a.pdf</a>)
and a policy covering treatment of multi drug resistant tuberculosis (TB) is being
developed. This new policy should be introduced from April 2015 and hopes to set policy
for Bedaquiline and possibly Delamanid, two drugs recently launched into the United
Kingdom market for multidrug resistant TB.</p><p> </p><p><strong> </strong></p><p>
</p><p><strong> </strong></p><p> </p>
|
 |
